Second Sight Medical Products

Equities

EYES

US81362J3086

Market Closed - Nasdaq Other stock markets 21:00:00 29/04/2024 BST			5-day change	1st Jan Change
1.63 ^USD	0.00%		-2.40%	-28.51%

2022	Vivani Medical Starts Nasdaq Trading Lower	MT
2022	Second Sight Medical Products, Inc.(NasdaqCM:EYES) dropped from NASDAQ Composite Index	CI

Second Sight Medical Products, Inc. Receives Grant from the National Institutes of Health

August 04, 2021 at 10:20 pm

Second Sight Medical Products, Inc. was notified on July 29, 2021, that it has received a grant from the National Institutes of Health to fund a patient preference information study of participants in its Early Feasibility Clinical Trial of a Visual Cortical Prosthesis. The entirety of the $155,964 grant will be provided to UCLA as a subcontractor to conduct the study. This study will help the Company better understand the benefits of the Orion Visual Cortical Prosthesis and the decision process of a person deciding whether or not to be implanted with the Orion Visual Cortical Prosthesis.

Latest news about Second Sight Medical Products

Vivani Medical Starts Nasdaq Trading Lower	31/08/22	MT
Second Sight Medical Products, Inc.(NasdaqCM:EYES) dropped from NASDAQ Composite Index	31/08/22	CI
Second Sight Medical Completes Merger With Nano Precision Medical; Changes Name to Vivani Medical	30/08/22	MT
Nano Precision Medical, Inc. completed the acquisition of Second Sight Medical Products, Inc. in a reverse merger transaction.	29/08/22	CI
Second Sight Medical Products Starts Trading on Split-Adjusted Basis; Shares Down	19/08/22	MT
Second Sight Medical Products, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/08/22	CI
Second Sight Medical Products, Inc. Announces Resignation of Edward Randolph as its Chief Operating Officer, Effective August 19, 2022	05/08/22	CI
Second Sight Medical Products, Inc. has Changed its Name to Vivani Medical, Inc	27/07/22	CI
Second Sight Medical Products Receives $1.1 Million of Funding for Visual Cortical Prosthesis Trial	18/07/22	MT
Second Sight Medical Products Announces Year Four NIH Funding of its Orion Study	18/07/22	CI
Second Sight Medical Products, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	16/05/22	CI
North American Morning Briefing : Dow Futures -2-	25/03/22	DJ
North American Morning Briefing : Stock Futures -3-	18/03/22	DJ
Transcript : Nano Precision Medical, Inc., Second Sight Medical Products, Inc. - M&A Call	08/02/22
Second Sight Medical Products to Acquire Nano Precision Medical in All-Stock Deal	08/02/22	MT
Nano Precision Medical, Inc. entered into term sheet to acquire Second Sight Medical Products, Inc. for approximately $180 million in a reverse merger transaction.	06/02/22	CI
Second Sight Medical Products, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	12/11/21	CI
Second Sight Medical Products, Inc.(NasdaqCM:EYES) added to S&P Global BMI Index	20/09/21	CI
Second Sight Medical Products, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	13/08/21	CI
Second Sight Medical Products : Obtains New NIH Grant Supplement for Visual Neuroprostheses Study	11/08/21	MT
Second Sight Medical Products, Inc. Receives Grant from the National Institutes of Health	04/08/21	CI
North American Morning Briefing : Stock Futures -3-	23/07/21	DJ
Certain Common Stock of Second Sight Medical Products, Inc. are subject to a Lock-Up Agreement Ending on 23-JUL-2021.	22/07/21	CI
Certain Stock Options of Second Sight Medical Products, Inc. are subject to a Lock-Up Agreement Ending on 23-JUL-2021.	22/07/21	CI
Certain Warrants of Second Sight Medical Products, Inc. are subject to a Lock-Up Agreement Ending on 23-JUL-2021.	22/07/21	CI

Chart Second Sight Medical Products

Duration

Period

More charts

Company Profile

Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing implantable visual prosthetics devices that restore vision to blind individuals. The Company manufactures neuromodulation devices for blindness and engaged in developing new technologies to treat sight-impaired individuals. Its approved product, the Argus II Retinal Prosthesis System (Argus II), treats outer retinal degenerations, such as retinitis pigmentosa (RP). It is engaged in developing the Orion Visual Cortical Prosthesis System (Orion), an implanted cortical stimulation device, which provides artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease and eye injury. Orion works by converting video images captured by a miniature camera housed in a user's glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes.

Sector

More about the company